FORT LAUDERDALE, Fla., March 22, 2017 /PRNewswire/ -- Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the acceptance of five abstracts regarding data related to studies conducted by the Company to better understand the performance characteristics of a combined salivary CD44 and total protein assay as an aid in the diagnosis of head and neck squamous cell carcinoma (HNSCC). The studies, along with others, helped provide direction for the clinical application of Vigilant Biosciences OncAlert®Oral Cancer and OncAlert Labs product lines as well as pipeline programs under development.
The abstracts will be presented at multiple conferences in the United States and abroad throughout March and April 2017. Details on the presentations follow.
Conference: International Association for Dental Research/IADR/AADR/CADR General Session and Exhibition, San Francisco, Calif., March 22-25, 2017
Poster title: "Assessment of an Oral Rinse, Qualitative, Point-of-care Assay to Predict Head and Neck Squamous Cell Carcinoma"
Session Title: Diagnostic Sciences VII
Poster Mode: Poster Session
Date: March 23, 3:45 p.m. - 5:00 p.m.
Presenter: Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer
Conference: American Association of Cancer Research (AACR) Annual Meeting 2017, Washington, D.C., April 1-5, 2017
Poster Title: "Strategies and Biomarkers for Clinical Prevention"
Session Category: Prevention Research
Poster Mode: Poster Session
Date: April 4, 8:00 a.m. - 12:00 p.m.
Presenter: Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer
Conference: American Association of Oral Medicine (AAOM) 2017 Annual Conference, Orlando, Florida, April 4-8, 2017
Poster Title: "Oral Point Of Care Test To Predict Head And Neck Squamous Cell Cancer"
Poster Mode: Oral Presentation
Date: April 8, 10:20 a.m.
Presenter: Michael Donovan, Ph.D., M.D., Chief Clinical Officer
Conference: AHNS 2017 Annual Meeting (held during the Combined Otolaryngology Spring Meetings (COSM), San Diego, CA, April 26-27, 2017
Poster Title: "Multivariate Oral Rinse Models Predict Head and Neck Squamous Cell Carcinoma"
Poster Mode: Poster Session
Date: April 27, 9:00 a.m. - 4:00 p.m.
Presenter: Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer
Conference: 2017 American Academy of Oral and Maxillofacial Pathology (AAOMP) Meeting, Newport, Rhode Island, April 28 – May 3, 2017
Poster Title: "Assessment of an Oral Rinse, Qualitative, Point-Of-Care Assay to Predict Head and Neck Squamous Cell Carcinoma"
Poster Mode: Read by Title
Presenter: Michael Donovan, Ph.D., M.D., Chief Clinical Officer
About Vigilant Biosciences Products
Vigilant Biosciences OncAlert Oral Cancer product line is based on patented technology that measures soluble CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. Vigilant's products currently include the
OncAlert Labs OraMark™ Test, a laboratory developed test available only through OncAlert Labs, a CLIA certified laboratory; and the OncAlert Oral Cancer product line, which includes the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test, both CE Marked and available in select markets outside the United States. Vigilant's accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus).
About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing.
For those who survive oral cancer diagnosed in the later stages, the treatment is painful, debilitating and often disfiguring. In addition, patients often struggle with eating and drinking, communicating and self-image. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMark™ Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.
SOURCE Vigilant Biosciences, Inc.